Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Iclusig for Certain Types of CML, ALL

Ariad news release; 2016 Nov 29

The FDA has approved Iclusig (ponatinib) to treat certain types of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Indications: Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase CML, or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.

Dosage and administration: 45 mg taken orally once daily. For hepatic impairment, 30 mg orally once daily.

Efficacy and safety: Approval is based on data from the PACE trial, which showed that 55% of chronic phase CML patients achieved major cytogenetic response.

Side effects/risks: Most common adverse reactions are abdominal pain, rash, constipation, headache, dry skin, fatigue, hypertension, pyrexia, arthralgia, nausea, diarrhea, lipase increased, vomiting, myalgia and pain in extremity.


Ariad announces FDA full approval and label update for Iclusig® (ponatinib) based on long-term efficacy and safety data from Phase 2 PACE clinical trial. [news release]. Cambridge, MA: Ariad Pharmaceuticals November 29, 2016. Accessed December 5, 2016.

Iclusig [package insert]. Cambridge, MA: Ariad Pharmaceuticals, Inc 2016. Accessed December 5, 2016.

This Week's Must Reads

Novel agents emerge for hemophilia, Shapiro AD, et al. J Thromb Haemost. 2018 Sep 28

Bleeding risk with acute myocardial infarction, Dodson JA et al. JACC Cardiovasc Interv. 2018 Nov 26;11:2287-96

Identifying thrombosis risk in ITP patients, Balitsky AK et al. Blood. 2018 Nov 8. doi: 10.1182/blood-2018-08-868406

Preop blood management lessons, Cahill CM et al. AABB 2018, Abstract PBM4-ST4-22

Treating osteoporosis caused by transfusion-dependent thalassemia , Terpos E et al. Blood Adv. 2018;2:2837-47

Must Reads in AML

Phase 2 results for combo therapy in relapsed AML, Daver N et al. Cancer Discov. 2018 Nov 8. doi: 10.1158/2159-8290.CD-18-0774

Transcription factor networks in AML, Assi SA et al. Nat Genet. 2018 Nov 12. doi: 10.1038/s41588-018-0270-1

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51